Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: testing methylphenidate for ADHD

To build a multimodal model combining neuropsychological, neurophysiological, and metabolomic measures to identify biomarkers predicting MPH-induced adverse effects and their underlying mechanisms, supporting individualized risk assessment in clinical practice.

Official registry: https://clinicaltrials.gov/study/NCT07900451 · National Taiwan University Hospital · enrollment listed as 90

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 90 people at Taipei. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Multimodal Neurobiological Investigation of Biomarkers Predicting Medication-Induced Adverse Effects in Children With Attention-Deficit/Hyperactivity Disorder

Interventions: methylphenidate

Primary outcome (registry wording): Questionnaire

Who it is for (from inclusion criteria)

  • Ages 6 Years to 16 Years
  • Participants, between the ages of 6 and 16 must meet the DSM-5 criteria for ADHD
  • At the time of initial evaluation, participants must exhibit a score greater than 3 on the Clinical Global Impressions scale for ADHD Severity (CGI-ADHD-S)
  • Cognitive assessment of participants must demonstrate a Full-Scale Intelligence Quotient (FSIQ) greater than 80

Public study contact (from the registry)

Chi-Yung Shang, MD, PhD

+886-2-23123456

cyshang@ntu.edu.tw

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBoston, Massachusetts
National Pregnancy Registry for Psychiatric Medications

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

NCT01246765 · Official ClinicalTrials.gov record · Massachusetts General Hospital

RecruitingNot a traditional drug phaseSacramento, California
Not a traditional drug phase: VR Treatment for ADHD

Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents.

NCT03221244 · Official ClinicalTrials.gov record · University of California, Davis

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: testing The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: for Coronavirus Infection (COVID-19)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to measure the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

NCT04278404 · Official ClinicalTrials.gov record · Duke University

FAQ about this NCT record

Is NCT07900451 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07900451?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07900451?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary